Deep Remission, Top-Down Treatment Strategies and Real-World Data in Patients with UC: An Interactive and Innovative Case Series

Tune in to this replay from a live CME Outfitters symposium, where expert faculty guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes for patients with ulcerative colitis.

 

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, June 8, 2018

Faculty

 

Maria T. Abreu, MD Maria T. Abreu, MD (Moderator)
Director, Crohn’s & Colitis Center
Martin Kalser Chair in Gastroenterology
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami Miller School of Medicine
Miami, FL

 

Arthur A. Kornbluth, MD Arthur A. Kornbluth, MD
Clinical Professor of Medicine
Inflammatory Bowel Disease Center
Henry D. Janowitz Division of Gastroenterology
Mount Sinai School of Medicine
New York, NY

 

Miguel Regueiro, MD, FACP, FACG, AGAF Miguel Regueiro, MD, FACP, FACG, AGAF
Professor of Medicine, Professor of Clinical and Translational Science
University of Pittsburgh School of Medicine
Associate Chief, Education
Division of Gastroenterology, Hepatology, and Nutrition
Clinical Medical Director of Inflmmatory Bowel Disease
Senior Medical Lead of Specialty Medical Homes
University of Pittsburgh Medical Center
Pittsburgh, PA

 

Statement of Need

Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and remissions. Traditionally, the goals of therapy for UC have entailed resolution of clinical symptoms such as rectal bleeding, bloody diarrhea, abdominal cramps, pain, and fatigue. However, treatment goals for UC have evolved to a treat-to-target strategy with targets such as mucosal/endoscopic healing, histologic healing, or deep remission (i.e., clinical, biochemical, and endoscopic remission) with the objective of preventing structural damage and disability. Conventional therapies have not been uniformly effective in achieving these aims, necessitating augmentation with steroids and carrying adverse risk often requiring discontinuation.

There has been an exponential growth in the pursuits of better targeted therapy to optimize IBD clinical outcomes. IBD therapies that explore new targets and inflammatory pathways are emerging to address the current treatment gaps observed with conventional and biologic therapies.

In this CME Outfitters symposium, expert faculty will guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
  • Apply the unique risk/benefit profiles of different biologic therapies when making treatment decisions based on individual prognosis and severity of disease.
  • Utilize data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.

The following learning objectives pertain only to those requesting CNE credit:

  • Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
  • Explain the unique risk/benefit profiles of different biologic therapies for making treatment decisions based on individual prognosis and severity of disease.
  • Describe data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers treating patients with ulcerative colitis (UC).

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:

Enduring: 0376-0000-17-011-H01-P

Type: knowledge-based

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21246 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

This program is not affiliated with Digestive Disease Week®.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Abreu reports she serves on the speaker’s bureau for AbbVie Inc.; and Imedex. She is a consultant for Eli Lilly and Company; Focus Medical Communications; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Theravance Biopharma US, Inc.; and UCB, Inc. She serves on the scientific advisory board for AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Roche Pharmaceuticals; and Shire.

Dr. Kornbluth reports that he receives research support from AbbVie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc. He serves on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited; Prometheus Laboratories Inc.; and Santarus, Inc./Salix Pharmaceuticals. He serves on the advisory board for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited; and Prometheus Laboratories Inc.

Dr. Reguiero reports that he is a consultant for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).